Just bumping this thread to give people the chance to read up on...

Just bumping this thread to give people the chance to read up on the Pitt Street valuations, the updated MST report, and the more recently released Triangle market sizing report, at the following link, https://raceoncology.com/april-2023-update/ prior to the release of the strategy update and the AGM. IMHO, you want to be fully armed so that you understand what the strategy is tackling.

To be clear, each of the MST Report https://wp-rac-2023.s3.ap-southeast-2.amazonaws.com/media/2023/11/mst-access-rac-update-07nov231699324908245.pdf, the Pitt Street report https://raceoncology.com/wp-content/uploads/2022/10/Race-Oncology-Pitt-Street-Research-Research-Initiation-Report-October-2022.pdf, and the Triangle report, see above, indicate primary market sizes in the tens of billions of dollars, their underlying valuations (or implied valuations) of RAC shares give results in the triple figures per share (that is, over $100 per share).

Now I know that our feeble human brains scream “if it looks to good to be true, it must be too good to be true” when they see things like 100 bags. Just distract your brain that was derived from that of an ape, by snacking on a packet of chips, and read any of these reports. Hell, get a big bag of Doritos and watch the Triangle Video.

And in each case, since the reports were released the events at RAC (RC220; Nagler 2 “Stunning” results; etc) mean that the outlook is even better than when the report came out.

If you can’t cope with any of that, remember that the really obvious opportunities that are right in front of us are worth say $5 or $10 per share.

Then note that the share price is about 90 cents; and that what the market is telling you is that it thinks this drug, which is better than it ever was before due to the new formulation, is less than a 1% chance of being approved, even though it has previously been approved before they even knew how to use it, or what it does.

To be clear, what it does is:
A. kill cancer in the clinic, it has been trialled in well over 1,000 patients, most recently right now, it cures people of cancer who can’t be cured by any other known method;
B. it’s also cardio protective with anti cancer synergy (exhibited in the lab and indicated in the clinic) when used in combo with massively popular anti cancer drugs that are known to be cardio-toxic (market size for just one of those drugs would be 22 million doses at $5,000 per dose [yes, that’s $110Bn USD annual market!]; and
C. it’s also the first-in-class and best-in-class FTO suppressant where FTO is super important for progression, immune avoidance and metastasis in 100’s of cancers, and also in obesity and in diabetes.

It’s likely that in the next fortnight they’ll release the strategy update about how to prove the highest priority results in the clinic, how to fund it while delivering outsized returns for shareholders (our biggest shareholder is a scientist who has been working on the strategy) and there will be a rollicking AGM.

Do your own research and have a good time! Remember that the market is a big group of people whose brains came from apes; and you can work to inform yourself of things they don’t know and facts that they don’t believe!